Lysogene SA is a France-based company principally engaged in the bio diagnostics and testing. The Company is focused on the gene therapy biotechnology. The Company develops treatments targeting severe genetic pathologies with central nervous system involvement and high unmet medical needs. It is specialized in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.